/
AVTX
$19.29+$1.09 (+5.99%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$956.7M
53M shares
52-week range
$4.61 – $24.27
75% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.55%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-8275.11
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.3M | $6.8M | $6.7M | $5.4M | $18.1M | $1.9M | $441.0K | $59.0K |
| Cost of revenue | $7.5M | −$566.5K | $300.0K | $1.5M | $3.4M | $1.3M | −$366.0K | $0 |
| Gross profit | $10.8M | $7.3M | $6.4M | $3.9M | $14.6M | $640.0K | $807.0K | $59.0K |
| Gross margin | 59.2% | 108.4% | 95.5% | 72.4% | 81.0% | 33.3% | 183.0% | 100.0% |
| R&D | $5.8M | $11.8M | $32.2M | $59.8M | $31.3M | $13.8M | $52.1M | $50.1M |
| Operating income | −$39.3M | −$16.1M | $0 | −$82.1M | −$37.4M | −$27.4M | −$68.5M | −$72.9M |
| EBITDA | −$13.1M | −$13.5M | −$45.5M | −$80.5M | −$37.3M | −$23.3M | −$34.8M | −$77.8M |
| Net income | −$40.1M | −$16.1M | −$63.5M | −$84.4M | −$41.7M | −$31.5M | −$35.1M | −$78.3M |
| Net margin | -218.5% | -238.1% | -947.9% | -1563.1% | -230.8% | -1639.5% | -7965.8% | -132642.4% |
| EPS (diluted) | -3317.28 | -819.74 | -2523.77 | -2330.66 | -1062.65 | -113.58 | -3.26 | -5.84 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-3.09 | $-4.23–$-2.12 | 10 |
| 2027 | $1M | $-3.03 | $-5.42–$-1.76 | 10 |
| 2028 | $13884 | $-2.86 | $-4.21–$-1.80 | 6 |
| 2029 | $11M | $-2.43 | $-2.43–$-2.43 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.99
Price
$19.29
Implied downside
-95%
Peer comparison
Avalo Therapeutics, Inc. Common Stock
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
www.avalotx.com- Employees
- 33
- IPO / List date
- Nov 13, 2015
- HQ
- WAYNE, PA
Held by traders on TradeandTell
No one on the platform currently holds AVTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 120,114 | $1.8M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-12-29 | 1-for-240reverse |
| 2022-07-08 | 1-for-12reverse |
| 2007-09-10 | 1-for-51reverse |
Recent trades on TradeandTell
No one on the platform has traded AVTX yet.
